Zum Hauptinhalt springen

fms related receptor tyrosine kinase 4

Der FLT4 gene provides instructions for making a protein called vascular endothelial growth factor receptor 3 (VEGFR-3), which regulates the development and maintenance of the lymphatic system. The lymphatic system produces and transports fluids and immune cells throughout the body. VEGFR-3 is turned on (activated) by two proteins called vascular endothelial growth factor C (VEGF-C) and vascular endothelial growth factor D (VEGF-D). When VEGF-C and VEGF-D attach (bind) to VEGFR-3, chemical signals are produced that regulate the growth, movement, and survival of lymphatic cells.

Videoauswahl für Gene
Videothek

Normal function

Der FLT4 gene provides instructions for making a protein called vascular endothelial growth factor receptor 3 (VEGFR-3), which regulates the development and maintenance of the lymphatic system. The lymphatic system produces and transports fluids and immune cells throughout the body. VEGFR-3 is turned on (activated) by two proteins called vascular endothelial growth factor C (VEGF-C) and vascular endothelial growth factor D (VEGF-D). When VEGF-C and VEGF-D attach (bind) to VEGFR-3, chemical signals are produced that regulate the growth, movement, and survival of lymphatic cells.

Conditions referring to this gene or chromosome

Other names

FLT41

fms-related tyrosine kinase 4

vascular endothelial growth factor receptor 3

VEGFR3

VGFR3_HUMAN

Related patient information and medicines

Mundkrebs

Patient information leaflet

Mundkrebs

Epidermal growth factor receptor monoclonal antibody (EGFR mAb) is one form of targeted therapy. Cetuximab is an EGFR mAb. Tyrosine kinase inhibitors (TKIs) are another. Immunotherapy is treatment that aims to boost the body's own immune system to destroy the cancer cells. It is also sometimes called biological therapy: Recombinant interleukin.

Chronische myeloische Leukämie

Patient information leaflet

Chronische myeloische Leukämie

Treatment for the initial chronic phase The aim of treatment is to control the disease process, to ease any symptoms and to prevent (or delay) the progress... You may be advised to have one or more of the following treatments: Imatinib tablets. This medicine is known as a tyrosine kinase inhibitor. The chemical tyrosine kinase is made by the.

Mastozytose und Mastzellenerkrankungen

Patient information leaflet

Mastozytose und Mastzellenerkrankungen

If the condition is severe, surgery to remove the spleen (splenectomy), medicines that have an effect on ... Dr Sarah Jarvis , 28th September 2021 Midostaurin for treating advanced systemic mastocytosis The National Institute for Health and Care Excellence (NICE) has brought out new guidance on the use of midostaurin for people with mastocytosis..

Fibromyalgie

Patient information leaflet

Fibromyalgie

Fibromyalgie ist a condition which causes pain and tenderness in the muscles and soft tissues in different areas of the body, associated with unrefreshing sleep and physical tiredness. The word Fibromyalgie means pain (-algia) coming from the muscles (my-) and fibrous tissues (fibro-) such as tendons and ligaments. Due to its wide range of.

Makuladegeneration

Patient information leaflet

Makuladegeneration

It is more common with increasing age. It is rare under the age of 60. It usually begins in one eye. About 5 in 100 people aged over 65 and about 12 in 100 people aged over 80 have AMD severe enough to cause serious visual impairment. Women are more likely than men to develop AMD. White people are more likely to develop AMD than those of African.

Leberfunktionstests

Patient information leaflet

Leberfunktionstests

They include substances that are made in the liver or affected by the health of the liver cells, chemicals which are processed or excreted by the liver, and hormones that the liver makes. What are liver function tests used for. Liver function tests are aimed at giving a picture of the 'state' of your liver. They are a sensitive way of looking for.

Weiterführende Lektüre und Referenzen

Artikelverlauf

Die Informationen auf dieser Seite werden von qualifizierten Klinikern verfasst und begutachtet.
  • 28. Juni 2022 | Neueste Version
  • 1 May 2008 | Ursprünglich veröffentlicht

Nehmen Sie an der Diskussion teil

Teilen Sie Ihre Gedanken oder Erfahrungen mit anderen in unserem Patientengemeinschaften.

Haftungsausschluss: The views expressed in the community do not represent medical advice. For any health concerns, consult your GP or healthcare provider.

Online-Apotheke, Behandlungen und Gesundheitsdienstleistungen

Einfacher Zugang zu vertrauenswürdigen Behandlungen und Gesundheitsdiensten online.

Common conditions

Get help with common conditions through the NHS, without a GP appointment.

Book your free Pharmacy First appointment

Abonnieren Sie den Patienten-Newsletter

Ihre wöchentliche Dosis klarer, vertrauenswürdiger Gesundheitsberatung - geschrieben, um Ihnen zu helfen, sich informiert, selbstbewusst und in Kontrolle zu fühlen.

Bitte geben Sie eine gültige E-Mail-Adresse ein

Durch das Abonnieren akzeptieren Sie unsere Datenschutzrichtlinie. Sie können sich jederzeit abmelden. Wir verkaufen Ihre Daten niemals.